China Hereditary Angioedema (HAE) Therapeutics market size stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
Hereditary angioedema (HAE) is a rare genetic disorder characterized by episodes of swelling (edema attacks) in different areas of the skin or the internal organs. In particular, it occurs in the upper respiratory tract and intestine. The China’s prevalence estimated at 1/50,000. Type 1 HAE (98.73%) accounts for the majority of Chinese HAE patients. Currently (in 2020) there are about 28,000 HAE Patients in China.
China is a growing market for hereditary angioedema (HAE) disease due to factors such as increasing frequency of symptoms in patients suffering with hereditary angioedema requiring immediate medical intervention. Increase in genetic mutations and supportive regulatory environment for hereditary angioedema drugs. In addition to these other factors such as affordable reimbursement scenario for treatment, increase in genetic mutations, healthcare reforms by government and increase in prevalence rate (in China 1/50,000) also contributing for growth of the market.
However, there are some restraining factors for growth of hereditary angioedema (HAE) therapeutics market in China such as lack of clinical practice guidelines, lack of regulatory approval of medicine, misdiagnosis and underdiagnosis of the disease.